New River kept at buy rating by Merrill

Merrill Lynch reiterated its buy rating for New River Pharmaceutical Inc. after Shire Pharmaceuticals submitted a citizen's petition to the FDA, which Merrill Lynch believes is meant to delay any generic launches of Shire drug Adderall XR, used to treat Attention Deficit-Hyperactivity Disorder. Merrill Lynch predicts that a delay of generic Adderall XR launches will give New River time to gain market share for its own ADHD drug, NRP104.

Shares of the Radford, Va.-based pharmaceutical company were up $1.87, or 4.19%, at $46.47 on volume of 36,422 versus the three-month running average of 87,927 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.